JP2018148853A - In-blood purine body metabolite reducing agent, food and drink, feed and pharmaceuticals - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide an in-blood purine body metabolite reducing agent for reducing purine body metabolites in the blood in a body, food and drink, feed and pharmaceuticals.SOLUTION: The present invention provides an in-blood purine body metabolite reducing agent for reducing purine body metabolites in the blood, containing calcium alginate as an active ingredient, food and drink, feed and pharmaceuticals.SELECTED DRAWING: None

Description

  The present invention relates to a blood purine metabolite lowering agent for lowering a purine metabolite in blood in the body, a food and drink, a feed and a medicine containing the blood purine metabolite lowering agent.

  Purine is a general term for substances having a purine skeleton, and is metabolized in the human body to become uric acid and excreted from the body, but when the amount of uric acid exceeds the excretion capacity and accumulates in the body, hyperuricemia is caused. It is. Hyperuricemia causes urate deposition such as gout and kidney damage.

  In order to reduce the uric acid level, lifestyle habits such as diet therapy and treatment with a hyperuricemia drug are performed. For the treatment of hyperuricemia and gout, for example, uric acid synthesis inhibitors such as allopurinol, uric acid excretion promoters such as benzbromarone and probenecid are used.

  However, these therapeutic agents have problems such as side effects. Therefore, there is a need for a safe and effective blood purine metabolite lowering agent for reducing purine metabolites in blood in the body.

  On the other hand, alginic acid is known as a natural polysaccharide contained in brown algae such as kombu and wakame. Alginic acid, alginates, and derivatives thereof are used in the food field as thickeners, stabilizers, gelling agents, and the like, and are also used in a wide range of applications such as pharmaceuticals, cosmetics, and textile processing.

  Alginic acid is a kind of dietary fiber. Among alginates, for example, sodium alginate is known to have a blood cholesterol lowering effect and a bowel movement improving effect. Patent Document 1 describes a cesium excretory agent containing calcium alginate as an active ingredient.

International Publication No. 2014/038630 Pamphlet

  The objective of this invention is providing the purine metabolite lowering agent in blood, food-drinks, feed, and a pharmaceutical for reducing the purine metabolite in blood in the body.

  The present invention is a blood purine metabolite lowering agent for reducing blood purine metabolite containing calcium alginate as an active ingredient.

  The present invention relates to a blood containing calcium alginate as an active ingredient, wherein 0.15 g or more of calcium alginate is orally administered to a human or an animal at 1 to 3 times per day for at least one day. It is a blood purine metabolite lowering agent for lowering purine metabolite in blood.

  The present invention is a food or drink containing the blood purine metabolite lowering agent.

  The present invention is a feed containing the blood purine metabolite lowering agent.

  The present invention is a pharmaceutical comprising the blood purine metabolite lowering agent.

  In the present invention, by containing calcium alginate as an active ingredient, it is possible to provide a blood purine metabolite lowering agent, food and drink, feed and pharmaceutical for reducing purine metabolite in blood in the body. .

  Embodiments of the present invention will be described below. This embodiment is an example for carrying out the present invention, and the present invention is not limited to this embodiment.

  The blood purine metabolite lowering agent for lowering blood purine metabolites in the body according to the embodiment of the present invention contains calcium alginate as an active ingredient. Moreover, the blood purine metabolite lowering agent for lowering blood purine metabolites in the body according to the present embodiment contains calcium alginate as an active ingredient, and 0.15 g or more of calcium alginate is It is used to be orally administered to humans or animals at 1 to 3 times per day for at least one day.

  The present inventors examined the effect of alginic acid and various alginates on reducing purine metabolites in the blood in the body. By using calcium alginate instead of sodium alginate or potassium alginate as an active ingredient, Or they found a new solution to reduce purine metabolites in blood in the animal body. Further, according to the blood purine metabolite lowering agent according to the present embodiment, since it contains calcium alginate as an active ingredient, for example, by taking orally, purine in blood in the human or animal body Metabolites can be reduced.

  Among the alginate, for example, sodium alginate is a water-soluble alginate, and the aqueous solution has a very high viscosity. Therefore, for example, when used in a drink, sodium alginate is reduced in molecular weight by a special method so that it can be consumed at a high concentration. Moreover, since sodium alginate is likely to increase the sodium load of the user when ingested at a high concentration, it is not desirable to use it for humans and the like who cannot be subjected to sodium load such as hypertension. Although it is possible to use potassium alginate, etc., which has little effect on blood pressure, potassium alginate is the same water-soluble alginate as sodium alginate, and its aqueous solution has a very high viscosity, so a low molecular weight is necessary. . In addition, excessive potassium alginate may cause hyperkalemia. Those having high viscosity after dissolution in water, such as sodium alginate and potassium alginate, become high viscosity even when blended into final products such as foods and drinks, and cause deterioration in texture. For these reasons, sodium alginate and potassium alginate are not suitable as blood purine metabolite lowering agents.

  On the other hand, since calcium alginate is a salt insoluble in water, even if it is a polymer, it can be taken regardless of the intake method, compared to sodium alginate and potassium alginate that need to be reduced in molecular weight, The said effect can be exhibited more. In addition, by using calcium alginate, there is little influence on hypertension, hyperkalemia, etc. that may occur when ingested at a high concentration such as sodium alginate or potassium alginate. Thus, calcium alginate does not have to be reduced in molecular weight, and is superior to sodium alginate and potassium alginate in reducing blood purine metabolites in the human or animal body, and at a high concentration. Even if ingested, it has little effect on hypertension, hyperkalemia, etc., so it can exert more effect on lowering purine metabolites in blood, and it is remarkably superior as a purine metabolite lowering agent in blood . In order to effectively exert physiological functions that reduce blood purine metabolites, it is desirable to continuously ingest foods and the like containing the ingredients for a long period of time. No matter how effective an ingredient is, it is difficult to continuously ingest a food or other food that deteriorates the texture when a necessary amount is blended, and as a result, a sufficient effect cannot be expected. The calcium alginate used in the blood purine metabolite lowering agent according to the present embodiment is hardly soluble or gelled because it is insoluble in water. Since it has almost no adverse effect on the texture, it enables continuous intake of active ingredients over a long period of time.

  Alginic acid is a biodegradable polymeric polysaccharide and is a polymer in which two types of uronic acids, D-mannuronic acid (M) and L-guluronic acid (G), are polymerized in a straight chain. More specifically, homopolymer fraction of D-mannuronic acid (MM fraction), homopolymer fraction of L-guluronic acid (GG fraction), and D-mannuronic acid and L-guluronic acid are randomly arranged This is a block copolymer in which the fractions (MG fraction) are bound arbitrarily. The composition ratio (M / G ratio) of D-mannuronic acid and L-guluronic acid of alginic acid varies mainly depending on the type of organism from which seaweed and the like are derived. The M / G ratio of calcium alginate used in the present embodiment is not particularly limited.

  Calcium alginate is a salt that is insoluble in water, whether it is a low molecule or a high molecule, and therefore hardly exhibits viscosity even when placed in water. The viscosity when calcium alginate used in this embodiment is converted to sodium alginate by an ion exchange reaction is not particularly limited, but may include a 10% aqueous solution having a viscosity of 60 mPa · s or more. More preferably, a 10% aqueous solution has a viscosity of 1000 mPa · s or more, more preferably a 1% aqueous solution has a viscosity of 100 mPa · s or more.

  Purine bodies that are targets of metabolite reduction suppression are a general term for substances having a purine skeleton, and are metabolized in the human body to become uric acid. Purine bodies include purine bases such as adenine, guanine and hypoxanthine, purine nucleosides such as adenosine, guanosine and inosine, and purine nucleotides such as adenylic acid, guanylic acid and inosinic acid. Uric acid is the final metabolite of purines in primates such as humans, but is further metabolized to allantoin in other mammals (such as mice) except primates, and further metabolized to allantoic acid, urea, and ammonia. Some animals go forward.

  Calcium alginate, which is an active ingredient, may be ingested by a single intake, or may be continuously ingested at least twice or more, but is preferably ingested continuously at least twice. As calcium alginate, as an effective intake, it is preferable that 0.15 g or more of calcium alginate is continuously ingested by humans or animals at least twice or more than a single intake. For example, calcium alginate has an effective intake of 0.15 g or more of calcium alginate at a rate of 1 to 3 times per day for humans or animals for at least 1 day, preferably at least 7 days, more preferably at least Preferably taken for 14 days, more preferably for at least 21 days, particularly preferably for at least 28 days, more particularly preferably for at least 35 days, and 0.4 g or more of calcium alginate is consumed per day for humans or animals. More preferably taken at least 3 days, preferably at least 7 days, more preferably at least 14 days, more preferably at least 21 days, particularly preferably at least 28 days, even more particularly preferably at least 35 days. 0.6g or more Calcium oxalate is administered to humans or animals 1 to 3 times per day for at least 1 day, preferably at least 7 days, more preferably at least 14 days, even more preferably at least 21 days, particularly preferably at least 28 days. More preferably still more preferably taken for at least 35 days, 2.4 g or more of calcium alginate is consumed 1 to 3 times per day for humans or animals for at least 1 day, preferably at least 7 days, It is particularly preferred that it is taken more preferably for at least 14 days, more preferably for at least 21 days, particularly preferably for at least 28 days, even more particularly preferably for at least 35 days.

  Although there is no restriction | limiting in particular in the upper limit of the effective intake of calcium alginate, For example, it is 10 mass% or less of the meal amount per day.

  The blood purine metabolite lowering agent according to this embodiment is more effective in lowering the purine metabolite in the body by being continuously administered at least twice or more than in a single administration. Is done.

  The blood purine metabolite lowering agent according to the present embodiment contains a pharmaceutical composition containing calcium alginate as an active ingredient and containing known pharmaceutically or pharmaceutically acceptable carriers and excipients and other additives. can do. The pharmaceutical composition can be used for pharmaceutical products such as tablets, powders, fine granules, capsules, pills, granules, sustained-release preparations, oral jelly preparations, oral liquid preparations and the like. The pharmaceutical composition may also contain auxiliary additives such as known stabilizers, thickeners, extenders, colorants and fragrances.

  A pharmaceutical product according to an embodiment of the present invention contains calcium alginate as an active ingredient, and is used for reducing purine metabolites in blood in the human or animal body.

  Here, “pharmaceuticals” include medical drugs that can be ingested containing calcium alginate, health foods developed for medical use, veterinary drugs developed for animals other than humans, and the like.

  Furthermore, it can be set as the food / beverage products aiming at reducing the purine metabolite in the blood in a human body by mix | blending the said calcium alginate with food / beverage products. Moreover, it can be set as the feed aiming at reducing the purine metabolite in the blood in an animal body by mix | blending the said calcium alginate with a feed.

  There are no particular restrictions on the food and drink to be blended, for example, beverages, baked goods, frozen confectionery, tablet confectionery, candy, gummi, jelly, caramel, jam, chocolate, gum, Japanese confectionery, soups, bread, various retort foods, side dishes, Examples include seafood products, ham, sausages, seasonings, and supplements. Moreover, there is no restriction | limiting in particular also in the feed to mix | blend, Livestock raising of a chicken, a cow, a pig, etc., the feed for fish culture, etc. are mentioned.

  The mixing ratio of the calcium alginate in the food or drink or feed is not particularly limited as long as it does not affect the main purpose of the food or drink or feed, and a wide range of usage is selected according to the product form. can do. Specifically, it is preferably 0.025 to 10% by mass or more when blended in soups, beverages, or feeds as a blending ratio per solid content of food or drink or feed, and blended in cookies or breads. When it does, it is preferable that it is 30-60 mass% or more. When blended in capsules or tablets, the content is preferably 60 to 100% by mass. When blended in a jelly-like or viscous liquid, it is preferably 0.025 to 10% by mass or more. In addition, if the calcium alginate is used as it is as a powder or tableted to obtain a food or drink or feed according to the present embodiment, a more natural food or drink or feed containing no additives can be obtained. Therefore, it is preferable.

  Hereinafter, although an example and a comparative example are given and the present invention is explained more concretely in detail, the present invention is not limited to the following examples.

In this example, the following materials were used.
Normal food: Rat feed AIN-93 (manufactured by CLEA Japan)
Lard: Yoneyama Pharmaceutical Co., Ltd. Pig oil (Lard)
Polymer calcium alginate: 1% aqueous solution viscosity of 108 mPa · s when sodium alginate is obtained by ion exchange reaction

  In the high fat diet, lard was added to the normal diet so as to be 14% by mass. High molecular weight calcium alginate was blended in a high fat diet at 2.5% by mass, 5% by mass, and 10% by mass, and dose dependency was examined.

<Examples 1-3>
[Preparation of lard calcium alginate feed]
Rat feed AIN-93 had a lard of 14% by mass and a high molecular weight calcium alginate of 2.5% by mass (Example 1), 5% by mass (Example 2), and 10% by mass (Example 3). Prepared by mixing.

<Comparative Example 1>
[Preparation of lard mixed feed]
It was prepared by mixing the rat feed AIN-93 so that the lard was 14% by mass.

<Test Example 1>
[Study of blood purine metabolite lowering effect]
Lard blended calcium alginate feed prepared in Examples 1 to 3 (polymer calcium alginate (Ca-Alg) is 2.5 mass%, 5 mass%, 10 mass%), lard blended diet prepared in Comparative Example 1 (HF : Control), the effect of lowering purine metabolites in blood of rats was compared.

  Each diet was given for 5 weeks, and rats (SD male rats (4 to 8 weeks old, n = 7) were bred, and uric acid level, allantoin level, blood urea nitrogen in plasma for 0 to 5 weeks The transition of (BUN) amount was measured. The amount of uric acid was measured using Uricase / TOOS method using Uric acid C-Test Wako (Wako Pure Chemical Industries), and the amount of allantoin was Mitsuhito Matsumoto (improved method for measuring plasma allantoin concentration. Research result information, 9: 27-28.1995.), And urea nitrogen content was measured using Quantum Cream Area Assay Kit <BUN, Detection Kit>: (BAS). Based on the average value of the cumulative amount of lard mixed feed (5 weeks) n = 7, the reference ratio of other cumulative amounts of food was calculated and corrected by dividing the body weight by the reference ratio. The results after 5 weeks are shown in Table 1.

  As a result, the amount of uric acid, which is a metabolite of purine, significantly increased in the lard-containing calcium alginate feed (polymer calcium alginate (Ca-Alg) 2.5% by mass, 5% by mass, 10% by mass). A decrease in blood urea nitrogen amount indicating the amount of allantoin, which is a metabolite, and the amount of urea, which is a metabolite of uric acid, was found, and it was found that calcium alginate has a blood purine metabolite lowering effect. There was no significant difference in food intake.

  Thus, by containing calcium alginate as an active ingredient, a drug for reducing purine metabolites in the blood in the body could be obtained. And the chemical | medical agent containing calcium alginate as an active ingredient exhibited the effect which reduces the purine metabolite in the blood in the body especially by administering continuously. By blending this drug into foods, drinks, feeds or pharmaceuticals, it is possible to obtain foods, drinks, feeds or drugs intended to reduce the purine metabolites in the blood in the body. Calcium alginate does not need to be reduced in molecular weight, and since it has less effect on hypertension, hyperkalemia, etc. even when taken at a higher concentration than sodium alginate and potassium alginate, purine metabolites in blood The effect of lowering can be further exerted, and it is remarkably excellent as a blood purine metabolite lowering agent.

Claims (5)

  A blood purine metabolite lowering agent for reducing a purine metabolite in blood, comprising calcium alginate as an active ingredient.   It contains calcium alginate as an active ingredient, and 0.15 g or more of calcium alginate is used to be orally administered to humans or animals at 1 to 3 times per day for at least one day, A purine metabolite lowering agent in blood for reducing purine metabolite in blood.   A food or drink comprising the blood purine metabolite lowering agent according to claim 1 or 2.   A feed comprising the blood purine metabolite lowering agent according to claim 1 or 2.   A pharmaceutical comprising the blood purine metabolite lowering agent according to claim 1 or 2.